1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014

Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014" provides data on the Refractory Multiple Myeloma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Multiple Myeloma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Multiple Myeloma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Refractory Multiple Myeloma 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Refractory Multiple Myeloma 25
Subjects Recruited Over a Period of Time 30
Clinical Trials by Sponsor Type 31
Prominent Sponsors 32
Top Companies Participating in Refractory Multiple Myeloma Therapeutics Clinical Trials 33
Prominent Drugs 35
Latest Clinical Trials News on Refractory Multiple Myeloma 36
Mar 05, 2014: Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma 36
Jan 22, 2014: Global Phase 3 Trial Commenced in Asia for Ixazomib, Takeda's Oral Proteasome Inhibitor 36
Dec 12, 2013: Clinical Study with Indatuximab Ravtansine (BT-062) in Multiple Myeloma shows good Tolerability and encouraging Efficacy in Combination with Lenalidomide and Dexamethasone 37
Nov 19, 2013: Oral Proteasome Inhibitor MLN9708 Enters into Phase 3 Clinical Study in Japan 38
Sep 10, 2013: Genmab Announces New Study of Daratumumab in Double Refractory Multiple Myeloma 38
Clinical Trial Profiles 40
Clinical Trial Overview of Top Companies 40
Celgene Corporation 40
Clinical Trial Overview of Celgene Corporation 40
Amgen Inc. 44
Clinical Trial Overview of Amgen Inc. 44
Johnson and Johnson 46
Clinical Trial Overview of Johnson and Johnson 46
Takeda Pharmaceutical Company Limited 48
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 48
Novartis AG 50
Clinical Trial Overview of Novartis AG 50
Merck and Co., Inc. 52
Clinical Trial Overview of Merck and Co., Inc. 52
F. Hoffmann-La Roche Ltd. 53
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 53
Pfizer Inc. 54
Clinical Trial Overview of Pfizer Inc. 54
Bristol-Myers Squibb Company 55
Clinical Trial Overview of Bristol-Myers Squibb Company 55
AbbVie Inc. 56
Clinical Trial Overview of AbbVie Inc. 56
Clinical Trial Overview of Top Institutes / Government 57
National Cancer Institute 57
Clinical Trial Overview of National Cancer Institute 57
Fred Hutchinson Cancer Research Center 60
Clinical Trial Overview of Fred Hutchinson Cancer Research Center 60
Mayo Clinic 63
Clinical Trial Overview of Mayo Clinic 63
The University of Texas M. D. Anderson Cancer Center 65
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 65
University of Arkansas 66
Clinical Trial Overview of University of Arkansas 66
Case Comprehensive Cancer Center 67
Clinical Trial Overview of Case Comprehensive Cancer Center 67
Memorial Sloan Kettering Cancer Center 68
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 68
City of Hope National Medical Center 69
Clinical Trial Overview of City of Hope National Medical Center 69
Washington University School of Medicine 70
Clinical Trial Overview of Washington University School of Medicine 70
Five Key Clinical Profiles 71
Appendix 163
Abbreviations 163
Definitions 163
Research Methodology 164
Secondary Research 164
About GlobalData 165
Contact Us 165
Disclaimer 165
Source 166

List of Tables
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Region, 2014* 7
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Refractory Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Refractory Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Refractory Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Refractory Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Refractory Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Refractory Multiple Myeloma Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Refractory Multiple Myeloma Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Refractory Multiple Myeloma Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 30
Refractory Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 31
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 32
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 35
Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014* 40
Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 44
Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson and Johnson, 2014* 46
Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014* 48
Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 50
Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 52
Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 53
Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 54
Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 55
Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014* 56
Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 57
Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014* 60
Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014* 63
Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 65
Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Arkansas, 2014* 66
Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014* 67
Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 68
Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by City of Hope National Medical Center, 2014* 69
Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014* 70

List of Figures
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Refractory Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Refractory Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Refractory Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Refractory Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Refractory Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 30
Refractory Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 31
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 32
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 33
Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 35
GlobalData Methodology 164

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the Netherlands

  • January 2017
    5 pages
  • Therapy  

  • Netherlands  

View report >

Global Therapy Market

  • January 2017
    32 pages
  • Therapy  

    Targeted Therap...  

    Monoclonal Anti...  

  • World  

View report >

Anti-Infective Market in India

  • January 2017
    4 pages
  • Anti-Infective  

    Blood Disease  

  • India  

    United States  

View report >

Therapy Market

1 day ago

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.